(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Ski Resorts Universally: A Colder time of year Wonderland Guide - 2Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- 3From Overpowered to Coordinated: Individual Accounts of Cleaning up
- 4The Most Compelling Innovation Developments Somewhat recently
- 5Fundamental Home Machines: An Easy to understand Determination Guide
- Wonderful Sea shores All over the Planet
- Manual for Famous people Known for Their Altruistic Endeavors
- Vote in favor of your #1 Kind of Cap
- Esteem Stuffed Gaming Workstations to Consider
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- How will the universe end?
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- WHO issues guidance on GLP-1 drugs for obesity
